PT-141 Dosing: 500mcg On-Demand Protocol

PT-141 (bremelanotide) is a cyclic melanocortin receptor agonist that works centrally in the brain to enhance sexual desire and arousal. Unlike PDE5 inhibitors that work peripherally on blood flow, PT-141 targets the melanocortin system in the hypothalamus.

PT-141 is FDA-approved for women with HSDD at 1.75 mg. Community protocols use lower doses (500 mcg) to balance efficacy with tolerability. This is not medical advice.

Quick Reference: Standard Protocol

For the full PT-141 peptide profile and vendor pricing, see our PT-141 peptide page.

Cycling Details

PT-141 is an on-demand medication — no loading phase, no fixed cycling. Use as needed, maximum once per 24 hours.

First-time use: Start at 500 mcg to assess tolerability. Nausea is common on initial doses but typically decreases with repeated use.

Tolerance management: Some users report decreased effectiveness with frequent use. Taking 1-2 weeks off every month may help maintain sensitivity.

Timing optimization: Effects begin 15-30 minutes post-injection and peak at 1-2 hours. Most people inject 30 minutes before anticipated activity.

Routes of Administration

Subcutaneous injection is the only practical route. Clinical trials and the FDA-approved formulation both use SC injection.

• Injection sites: Abdomen, thigh, upper arm — anywhere with subcutaneous fat
• Volume: 0.1 mL with an insulin syringe (29-31 gauge)
• Not oral: PT-141 is a cyclic peptide degraded by stomach acid
• Not nasal: Early research explored nasal delivery, but SC proved more reliable

Reconstitution Quick Reference

Math: 10 mg / 2 mL = 5 mg/mL = 5,000 mcg/mL. For 500 mcg: 500 / 5,000 = 0.1 mL = 10 units.

Swirl gently — do not shake. Refrigerate at 2-8 C, use within 28 days.

Where These Numbers Come From

Community PT-141 protocols are informed by extensive clinical trial data, including the FDA-approved regimen.

FDA-approved dose: 1.75 mg SC for HSDD in premenopausal women. The RECONNECT Phase III trials in 1,267 women showed significant improvement in sexual desire and distress reduction (Kingsberg et al., 2019).

Male studies: Doses of 7-20 mg showed efficacy in men with ED, though with higher nausea rates. Lower doses (1-2 mg) showed particular promise for psychogenic ED (Wessells et al., 2000).

Why community doses are lower: 500 mcg-1 mg balances efficacy against nausea (which increases substantially at higher doses). Individual variation means some achieve desired effects well below the FDA dose. Male users may need slightly lower doses than the female FDA protocol.

Stacking Protocols

Start compounds separately to assess individual response. Nausea from PT-141 may be amplified by other compounds.

Side Effects & Safety

• Nausea — 40%+ in clinical trials, most common side effect, usually mild-moderate
• Flushing — facial warmth and redness, typically brief
• Headache — usually mild, resolves within hours
• Injection site reactions — redness, minor swelling
• Fatigue and dizziness — less common
• Max frequency: Once per 24 hours — more frequent dosing increases nausea without additional benefit
• Pregnancy: Contraindicated (category X)
• Nausea management: Start at 500 mcg, take with light food, ginger supplements may help, tolerance develops with repeated use

Frequently Asked Questions

What is the standard PT-141 dose?

500 mcg subcutaneous injection, taken 30 minutes before sexual activity, as needed. Maximum once per 24 hours. This is lower than the FDA-approved 1.75 mg, chosen to balance efficacy with tolerability.

How long before activity should I take PT-141?

30 minutes is the most common timing. Effects begin within 15-20 minutes and peak at 1-2 hours post-injection.

Can PT-141 be used daily?

No — maximum one dose per 24 hours. PT-141 is an as-needed medication, not a daily protocol.

What's the difference between PT-141 and Melanotan-II?

PT-141 is a modified version of Melanotan-II designed specifically for sexual function, with reduced tanning effects. PT-141 targets MC3R/MC4R in the brain; MT-II has broader effects including skin pigmentation.

Does PT-141 work for both men and women?

Clinical studies show efficacy in both sexes, though FDA approval is only for women with HSDD. Men use it off-label at similar community doses.

How do I reconstitute PT-141?

Add 2 mL bacteriostatic water to a 10 mg vial (5,000 mcg/mL). 500 mcg = 10 units on an insulin syringe. Swirl gently, refrigerate, use within 28 days.

Related Guides

• PT-141 Benefits — 6 research-backed effects ranked by evidence
• PT-141 Results Timeline — What to expect from first dose through repeated use
• PT-141 Bloodwork Guide — 5 labs to monitor for safety
• PT-141 vs Melanotan 2 — Head-to-head sexual function comparison
• Kisspeptin vs PT-141 — Hormonal vs neural approaches to sexual health
• Oxytocin Benefits Guide — Research-backed effects on bonding and social cognition
• Oxytocin Dosing Guide — Bonding neuropeptide for intimacy stacking
• Peptide Stacking Guide — Principles for combining peptides
• Calculate Your PT-141 Cycle Cost — estimate vials needed and total cost for your protocol
• Peptides and TRT: 8 Synergies That Amplify Results — how PT-141 pairs with TRT for libido

References

For educational and research purposes only. This is not medical advice. PT-141 is FDA-approved for specific indications; off-label use should be discussed with a healthcare provider.